Drug profile

The FDA adverse-event record for Unknown Topical Flea Product

24 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Unknown Topical Flea Product. See the species affected, top reactions, and outcomes below.

24
adverse-event reports
16.7%
death-coded share
Dog
most-reported species
15
Lack of efficacy (ectoparasite) - flea - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
24
Total Reports
4
Deaths Reported
16.7%
Death Rate

Active Ingredients

Unknown Topical Flea Product

Administration Routes

TopicalUnknown

Species Affected

Dog 20
Cat 4

Most Affected Breeds

Chihuahua 6
Crossbred Canine/dog 5
Domestic Shorthair 3
Retriever - Labrador 2
Newfoundland 1
Shepherd Dog - German 1
Setter - English 1
Maine Coon 1
Shih Tzu 1
Great Pyrenees 1

Most Reported Reactions

Lack of efficacy (ectoparasite) - flea 15
Lack of efficacy - NOS 7
Panting 3
Lethargy (see also Central nervous system depression in 'Neurological') 2
Scratching 2
Death 2
Hind limb ataxia 2
Lateral recumbency 2
Dilated pupils 2
Abnormal pupil light reflex 2
Increased lung sounds 2
Tachypnoea 2

Outcome Breakdown

Outcome Unknown
14 (58.3%)
Recovered/Normal
4 (16.7%)
Ongoing
2 (8.3%)
Died
2 (8.3%)
Euthanized
2 (8.3%)

Unknown Topical Flea Product Adverse Event Insights

24 reports name Unknown Topical Flea Product; 4 recorded a death outcome (16.7% of reported events, not a population-level mortality rate). Active ingredient: Unknown Topical Flea Product. Administration routes: Topical, Unknown.

By species: Dog (20 reports), Cat (4 reports). By breed: Chihuahua (6), Crossbred Canine/dog (5), Domestic Shorthair (3).

Leading clinical signs: Lack of efficacy (ectoparasite) - flea (15), Lack of efficacy - NOS (7), Panting (3), Lethargy (see also Central nervous system depression in 'Neurological') (2). Outcome, 24 coded reports: Outcome Unknown leads at 58.3%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.